Biologic Therapy in Psoriasis: A Comprehensive Review of Molecular Targets and Personalized Clinical Management

Psoriasis is a chronic, immune-mediated inflammatory skin disease marked by complex interactions among genetic susceptibility, dysregulated cytokine signaling, keratinocyte activation, and systemic inflammation. Biologic therapies have transformed management by selectively targeting key inflammatory pathways, particularly tumor necrosis factor-alpha (TNF-α), IL-12/23, IL-17, and IL-23. This review aims to summarize the molecular basis, clinical efficacy, safety, treatment selection, and emerging personalization strategies associated with biologic therapy in psoriasis. A structured literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for relevant publications from 2016 to 2026, with selection based on predefined inclusion and exclusion criteria. Current evidence indicates that certain IL-17 and IL-23 inhibitors have demonstrated high rates of skin clearance in clinical trials, with differences in response onset and durability depending on the specific agent, patient population, and trial comparison, whereas TNF-α inhibitors retain value in selected patients, particularly those with psoriatic arthritis and established long-term response. Treatment choice is increasingly influenced by comorbidities, prior biologic exposure, infection risk, reproductive considerations, obesity, treatment persistence, and patient preference. Biomarkers, pharmacogenomics, therapeutic drug monitoring, multi-omic profiling, and artificial intelligence-based predictive models may further support individualized treatment selection, although these approaches remain largely investigational and are not sufficiently validated for routine biologic selection. Biologic therapy has substantially improved psoriasis outcomes, although long-term comparative safety, cost, accessibility, and validation of predictive tools remain important priorities for precision clinical management.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-16
DOI
https://doi.org/10.7759/cureus.119798
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biologic Therapy in Psoriasis: A Comprehensive Review of Molecular Targets and Personalized Clinical Management

Prathyusha Dasari, Sanjeev Gulati, Dr. Karthika Padmavathy, Kinjal M. Vasava et al.
Cureus
Psoriasis: Treatment and Pathogenesis
article

Biologic Therapy in Psoriasis: A Comprehensive Review of Molecular Targets and Personalized Clinical Management

Prathyusha Dasari, Sanjeev Gulati, Dr. Karthika Padmavathy, Kinjal M. Vasava, Md Samim Shikari, Jaya Sai Sankara Vara Prasad Kommana
article en

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disease marked by complex interactions among genetic susceptibility, dysregulated cytokine signaling, keratinocyte activation, and systemic inflammation. Biologic therapies have transformed management by selectively targeting key inflammatory pathways, particularly tumor necrosis factor-alpha (TNF-α), IL-12/23, IL-17, and IL-23. This review aims to summarize the molecular basis, clinical efficacy, safety, treatment selection, and emerging personalization strategies associated with biologic therapy in psoriasis. A structured literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for relevant publications from 2016 to 2026, with selection based on predefined inclusion and exclusion criteria. Current evidence indicates that certain IL-17 and IL-23 inhibitors have demonstrated high rates of skin clearance in clinical trials, with differences in response onset and durability depending on the specific agent, patient population, and trial comparison, whereas TNF-α inhibitors retain value in selected patients, particularly those with psoriatic arthritis and established long-term response. Treatment choice is increasingly influenced by comorbidities, prior biologic exposure, infection risk, reproductive considerations, obesity, treatment persistence, and patient preference. Biomarkers, pharmacogenomics, therapeutic drug monitoring, multi-omic profiling, and artificial intelligence-based predictive models may further support individualized treatment selection, although these approaches remain largely investigational and are not sufficiently validated for routine biologic selection. Biologic therapy has substantially improved psoriasis outcomes, although long-term comparative safety, cost, accessibility, and validation of predictive tools remain important priorities for precision clinical management.

Cureus
KPC Medical College and Hospital (IN), R. G. Kar Medical College and Hospital (IN), Dayananda Sagar University (IN), Medical College and Hospital, Kolkata (IN)
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon